Suven Pharmaceuticals Limited (SUVENPHAR) - Total Liabilities

Latest as of March 2025: Rs11.91 Billion INR ≈ $128.81 Million USD

Based on the latest financial reports, Suven Pharmaceuticals Limited (SUVENPHAR) has total liabilities worth Rs11.91 Billion INR (≈ $128.81 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Suven Pharmaceuticals Limited asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Suven Pharmaceuticals Limited - Total Liabilities Trend (2019–2025)

This chart illustrates how Suven Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SUVENPHAR current and non-current assets.

Suven Pharmaceuticals Limited Competitors by Total Liabilities

The table below lists competitors of Suven Pharmaceuticals Limited ranked by their total liabilities.

Company	Country	Total Liabilities
Aurizon Holdings Ltd AU:AZJ	Australia	AU$7.48 Billion
Choice Hotels International Inc NYSE:CHH	USA	$2.85 Billion
Premier Energies Limited NSE:PREMIERENE	India	Rs65.35 Billion
KONINKLIJKE VOP.UNSP.ADR F:VPK	Germany	€3.54 Billion
Novanta Inc F:1GSN	Germany	€704.34 Million
Hongda SHG:600331	China	CN¥587.78 Million
Union Bank of Taiwan Pref TW:2838A	Taiwan	NT$970.36 Billion
Acm Research Inc NASDAQ:ACMR	USA	$982.43 Million

Liability Composition Analysis (2019–2025)

This chart breaks down Suven Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Suven Pharmaceuticals Limited (SUVENPHAR) net asset quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.43	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.70	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.39	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Suven Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Suven Pharmaceuticals Limited (2019–2025)

The table below shows the annual total liabilities of Suven Pharmaceuticals Limited from 2019 to 2025.

Year	Total Liabilities	Change
2025-03-31	Rs11.91 Billion ≈ $128.81 Million	+485.53%
2024-03-31	Rs2.03 Billion ≈ $22.00 Million	-11.77%
2023-03-31	Rs2.31 Billion ≈ $24.93 Million	-23.76%
2022-03-31	Rs3.02 Billion ≈ $32.70 Million	+2.98%
2021-03-31	Rs2.94 Billion ≈ $31.76 Million	-10.48%
2020-03-31	Rs3.28 Billion ≈ $35.48 Million	+70.21%
2019-03-31	Rs1.93 Billion ≈ $20.84 Million	--

About Suven Pharmaceuticals Limited

NSE:SUVENPHAR India Drug Manufacturers - Specialty & Generic

Market Cap

$4.40 Billion

Rs406.97 Billion INR

Market Cap Rank

#3890 Global

#169 in India

Share Price

Rs1063.80

Change (1 day)

+0.00%

52-Week Range

Rs1063.80 - Rs1063.80

All Time High

Rs1334.20